Immunotherapy Response in MMR-Deficient Tumors Linked to MSI Levels, Indel Mutations

NEW YORK (GenomeWeb) – Response to anti-PD-1 checkpoint blockade immunotherapy in tumors with mismatch repair (MMR) defects depends on a tumor's overall mutational load and its level of microsatellite instability, as well as the relative proportion of small insertion and deletion (indel) mutations, new research in mouse models and human samples suggests.